Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) Income from Continuing Operations (2018 - 2025)

Historic Income from Continuing Operations for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to -$7.1 million.

  • Exagen's Income from Continuing Operations fell 4095.07% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.0 million, marking a year-over-year decrease of 1269.68%. This contributed to the annual value of -$15.1 million for FY2024, which is 3619.4% up from last year.
  • Exagen's Income from Continuing Operations amounted to -$7.1 million in Q3 2025, which was down 4095.07% from -$4.4 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Income from Continuing Operations registered a high of -$3.0 million during Q2 2024, and its lowest value of -$15.1 million during Q4 2022.
  • In the last 5 years, Exagen's Income from Continuing Operations had a median value of -$6.2 million in 2021 and averaged -$6.8 million.
  • In the last 5 years, Exagen's Income from Continuing Operations crashed by 12886.12% in 2022 and then soared by 6582.82% in 2023.
  • Quarter analysis of 5 years shows Exagen's Income from Continuing Operations stood at -$7.1 million in 2021, then crashed by 114.33% to -$15.1 million in 2022, then skyrocketed by 63.35% to -$5.5 million in 2023, then soared by 32.11% to -$3.8 million in 2024, then tumbled by 88.43% to -$7.1 million in 2025.
  • Its Income from Continuing Operations stands at -$7.1 million for Q3 2025, versus -$4.4 million for Q2 2025 and -$3.8 million for Q1 2025.